- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HCC | Clinical
Chinese Study Finds That Sintilimab and Biosimilar Bevacizumab Prolong HCC PFS
July 23, 2021
Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.
Clear Efficacy Benefit Not Shown With Atezolizumab/Bevacizumab Versus Lenvatinib in Unresectable HCC
July 19, 2021
A network meta-analysis looking at 4 studies that assessed atezolizumab/bevacizumab compared to lenvatinib showed there was not a statistically significant improvement for patients with unresectable hepatocellular carcinoma.
Tiselizumab’s Mechanism of Action in Patients with Hepatocellular Carcinoma
July 19, 2021
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.
Prospective Findings of TTFields/Sorafenib in Advanced HCC May Warrant a Randomized Study
July 16, 2021
In an interview with Targeted Oncology, HEPANOVA EF-30 investigator, Eleni Gikka, MD, provided insight into the use of TTFields in combination with standard of care therapy for patients with advanced hepatocellular carcinoma.
Improving Overall Survival and Response Rates in HCC With Tumor Targeting
July 13, 2021
Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.
Phase 2 Trials Currently Filling Unmet Needs in Advanced HCC
July 01, 2021
A phase 2 trial of tislelizumab and another trial of Tumor Treating Fields accompanied by sorafenib are filling unmet needs in advanced hepatocellular carcinoma, although more data are still needed in this space.
Post Hoc Analysis Suggests Lenvatinib Therapy May Continue in Patients with Unresectable HCC, Child–Pugh class Liver Function
July 01, 2021
Patients with unresectable hepatocellular carcinoma with Child-Pugh class B liver function experienced a similar tumor size reduction as their Child-Pugh class A counterparts, all treated with lenvatinib, according to a post-hoc analysis of the phase 3 REFLECT study.
Akce Gives Insights on How Immunotherapy is Changing the HCC Treatment Landscape
June 28, 2021
As June is Cancer Immunotherapy Month, Mehmet Akce, MD, discusses the future of immunotherapy in HCC in an interview with Targeted Oncology.
Cabozantinib Plus Atezolizumab Reduces Risk of Disease Progression or Death in Advanced HCC
June 28, 2021
The combination of cabozantinib and atezolizumab demonstrated improvement in both progression-free and overall survival compared with sorafenib, in patients with untreated advanced hepatocellular carcinoma.
Novel Combination of Sintilimab and Bevacizumab Biosimilar IBI305 Shows Significant Survival Benefit in HCC
June 23, 2021
New published data from a phase 2/3 trial shows the increased survival benefit of PD-1 inhibitor sintililmab and bevacizumab biosimilar IBI305 in the frontline setting for patients with metastatic HCC.